Chatbot for HIV Prevention
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a chatbot designed to increase awareness and use of PrEP, a medication that helps prevent HIV. It focuses on Black men who have sex with men in the Southern U.S., aiming to support safer sexual practices. The study compares those using the chatbot with a control group to evaluate its effectiveness. Eligible participants must be HIV-negative Black men, over 18, with internet access, who haven't been on HIV treatment and have had condomless sex with another man in the last six months. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance HIV prevention strategies.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you have received antiretroviral therapy (ART) treatment.
What prior data suggests that this chatbot is safe for promoting PrEP awareness?
Research has shown that using chatbots to help prevent HIV is safe. One study found these chatbots practical and well-received for encouraging HIV testing and the use of PrEP, a medicine that helps prevent HIV. Chatbots offer anonymous and ongoing support, allowing people to learn about HIV prevention without any known risks. Although chatbots continue to improve, no safety issues have been reported in their use for this purpose.12345
Why are researchers excited about this trial?
Researchers are excited about using chatbots for PrEP awareness because they offer a unique way to engage people in HIV prevention. Unlike traditional methods like in-person counseling or pamphlets, chatbots can provide personalized information and support 24/7 through digital platforms. This accessibility and adaptability make them a potentially powerful tool for reaching wider audiences, particularly tech-savvy individuals or those who prefer private, digital interactions. By enhancing awareness and understanding of PrEP through interactive conversations, chatbots could significantly improve HIV prevention efforts.
What evidence suggests that this chatbot is effective for promoting PrEP awareness among Black men who have sex with men?
Research has shown that chatbots can effectively provide accurate information about preventing HIV. In this trial, participants in the intervention group will interact with a chatbot designed to increase PrEP awareness. Studies have found that AI chatbots give clear and unbiased advice on HIV topics. One study highlighted their potential to increase the use of PrEP, a medication that helps prevent HIV, by sharing important health information. Chatbots have been evaluated for their ability to customize responses for each user, making the information more relevant and engaging. Overall, while chatbots seem promising in raising awareness about PrEP, more work is needed to address any ethical and practical concerns.12678
Who Is on the Research Team?
Zhao Ni
Principal Investigator
Yale University
Are You a Good Fit for This Trial?
This trial is for cisgender Black men who have sex with men (MSM), are at least 18 years old, speak English, and have had condomless sex in the past 6 months. They must be HIV negative or untested and have Internet access.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants engage with a chatbot intervention to promote PrEP awareness and uptake
Follow-up
Participants are monitored for changes in PrEP awareness and uptake, usability, and other secondary outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Chatbot for PrEP Awareness
Trial Overview
The study is testing a chatbot designed to increase awareness and use of PrEP (a medication to prevent HIV) among Black MSM in the Southern US compared to general educational messages about PrEP.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
Gilead Sciences
Industry Sponsor
Daniel O'Day
Gilead Sciences
Chief Executive Officer since 2019
MBA from Columbia University
Dietmar Berger
Gilead Sciences
Chief Medical Officer
MD and PhD from Albert-Ludwigs University School of Medicine
Published Research Related to This Trial
Citations
Chatbots for HIV Prevention and Care: a Narrative Review
Chatbots in HIV prevention and care show potential; however, significant work remains in addressing associated ethical and practical concerns.
Evaluating AI chatbots for HIV prevention: An assessment ...
A new CHPRC analysis evaluates the quality of the HIV-related information provided by ChatGPT and other popular chatbots powered by artificial intelligence (AI)
3.
publichealth.berkeley.edu
publichealth.berkeley.edu/articles/spotlight/research/study-explores-effectiveness-of-ai-chatbots-in-hiv-preventionNew study explores effectiveness of AI chatbots in HIV ...
High Response Accuracy, but Variable Clarity: AI chatbots can provide HIV prevention information and guidance that is accurate and neutral in ...
Improving HIV Pre-exposure Prophylaxis Uptake with ...
The United Nations Educational, Scientific and Cultural Organization created an AI chatbot named Eli to answer questions on HIV prevention in 2020, followed by ...
Evaluating the Usability of an HIV Prevention Artificial ...
The AI chatbot demonstrated high feasibility in delivering HIV self-testing kits and providing clinical information on HIV testing, PrEP, and ...
Testing the Feasibility and Acceptability of Using an Artificial ...
Conclusions: The current AI chatbot is feasible and acceptable to promote the uptake of HIV testing and PrEP. To ensure the successful ...
Protocol for chatbot implementation and evaluation
Chatbots have the potential to reduce barriers to HIV treatment and PrEP by providing anonymous and continuous support.
Chatbot informs women about HIV prevention
The new chatbot will help women worldwide learn about and choose their preferred HIV prevention method.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.